| The La-related proteins, a family with connections to cancer C Stavraka, S Blagden Biomolecules 5 (4), 2701-2722, 2015 | 135 | 2015 |
| Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions C Stavraka, H Rush, P Ross Journal of hepatocellular carcinoma, 11-21, 2018 | 116 | 2018 |
| A study of symptoms described by ovarian cancer survivors C Stavraka, A Ford, S Ghaem-Maghami, T Crook, R Agarwal, H Gabra, ... Gynecologic oncology 125 (1), 59-64, 2012 | 110 | 2012 |
| Risk of ovarian cancer relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer I Rizzuto, C Stavraka, J Chatterjee, J Borley, TG Hopkins, H Gabra, ... International Journal of Gynecologic Cancer 25 (3), 2015 | 56 | 2015 |
| An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials DJ Pinato, C Stavraka, MJ Flynn, MD Forster, SM O'Cathail, MJ Seckl, ... PloS one 9 (1), e83279, 2014 | 49 | 2014 |
| Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation TG Hopkins, C Stavraka, H Gabra, L Fallowfield, C Hood, S Blagden Climacteric 18 (1), 94-98, 2015 | 47 | 2015 |
| First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer S Blagden, A Olmin, D Josephs, C Stavraka, A Zivi, DJ Pinato, A Anthoney, ... Clinical Cancer Research 20 (23), 5908-5917, 2014 | 44 | 2014 |
| Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer J van de Haar, X Ma, SN Ooft, PW van der Helm, LR Hoes, S Mainardi, ... Nature Medicine 29 (3), 605-614, 2023 | 41 | 2023 |
| Biliary tract cancers: molecular heterogeneity and new treatment options N Personeni, A Lleo, T Pressiani, F Colapietro, MR Openshaw, ... Cancers 12 (11), 3370, 2020 | 37 | 2020 |
| Basophils from cancer patients respond to immune stimuli and predict clinical outcome HJ Bax, J Chauhan, C Stavraka, A Khiabany, M Nakamura, G Pellizzari, ... Cells 9 (7), 1631, 2020 | 30 | 2020 |
| Coagulopathy in COVID-19 infection: a case of acute upper limb ischemia N Galanis, C Stavraka, F Agathangelidis, E Petsatodis, C Giankoulof, ... Journal of surgical case reports 2020 (6), rjaa204, 2020 | 30 | 2020 |
| Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes HJ Bax, J Chauhan, C Stavraka, A Santaolalla, G Osborn, A Khiabany, ... British Journal of Cancer 128 (2), 342-353, 2023 | 28 | 2023 |
| IgE antibodies against cancer: efficacy and safety J Chauhan, AJ McCraw, M Nakamura, G Osborn, HS Sow, VF Cox, ... Antibodies 9 (4), 55, 2020 | 27 | 2020 |
| How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoid treatment? V Narwani, L Swafe, C Stavraka, K Dhatariya Clinical Medicine 14 (3), 327, 2014 | 26 | 2014 |
| A study to evaluate the cause of bone demineralization in gynecological cancer survivors C Stavraka, K Maclaran, H Gabra, R Agarwal, S GhaemMaghami, ... The oncologist 18 (4), 423-429, 2013 | 26 | 2013 |
| Insights from IgE immune surveillance in allergy and cancer for anti-tumour IgE treatments AJ McCraw, J Chauhan, HJ Bax, C Stavraka, G Osborn, M Grandits, ... Cancers 13 (17), 4460, 2021 | 25 | 2021 |
| The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer AR Naqash, AJ Kihn-Alarcón, C Stavraka, K Kerrigan, SM Vareki, ... Annals of Translational Medicine 9 (12), 2021 | 24 | 2021 |
| IgE activates monocytes from cancer patients to acquire a pro-inflammatory phenotype M Nakamura, EA Souri, G Osborn, R Laddach, J Chauhan, C Stavraka, ... Cancers 12 (11), 3376, 2020 | 23 | 2020 |
| Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations A Pouptsis, L Swafe, M Patwardhan, C Stavraka Frontiers in oncology 10, 553080, 2020 | 23 | 2020 |
| Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer J Spicer, B Basu, A Montes, U Banerji, R Kristeleit, GJ Veal, C Corrigan, ... Cancer research 80 (16_Supplement), CT141-CT141, 2020 | 23 | 2020 |
Thomas Glass HopkinsGSK在 gsk.com 的电子邮件经过验证
